Dong-Hui Huang, [email protected]
BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC
As with drugs, the most advanced biologics are repurposed: follitropin delta and follitropin alpha are routinely used in fertility treatments, and evaluated for endometriosis patients in Phase III studies, but not beyond this indication
How It Works Sermorelin is a GHRH analog that stimulates natural growth hormone production from the pituitary
Certificate of Analysis included minimum 99% purity guaranteed Research orientation Select Size Independently verified for purity and identity by Janoshik Analytical
Each batch undergoes particle-size verification (100-300nm), encapsulation integrity testing, and stability assessment before release, ensuring consistent potency
